Faculty Advisor(s)

Kevin Seale

Document Type


Publication Date



© 2022 Jordan Kelley


Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer. Lung cancer leads all cancer death rates worldwide. Surgical treatment for NSCLC warrants a role for the anesthetist to influence recurrence-free survival, overall survivability, and overall mortality. Literature suggests propofol and sevoflurane are linked to immunosuppressive characteristics by decreasing immunity via different mechanisms. Propofol has known anti-inflammatory effects, but studies reveal sevoflurane has similar capabilities. Sevoflurane may attenuate the metastatic potential of lung cancer by stopping platelet activation, but sevoflurane may also enhance other pathways of metastasis. Similarly, propofol has anti-metastatic abilities, hindering angiogenesis by downregulating necessary growth factors. Propofol and sevoflurane influence various NSCLC growth and metastasis mechanisms, but research is inconclusive on how propofol or sevoflurane definitively affects outcomes with NSCLC. Heterogenous clinical evidence supports a propofol TIVA for improved recurrence-free survivability, increased overall survivability, and decreased overall mortality more than inhalation anesthetics. Ultimately, more research is needed to justify the preferred anesthetic.


Master's capstone



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.